Crizotinib, a multiple small-molecule inhibitor of ALK, mesenchymal-epithelial transition (MET) and c-ros oncogene 1 (ROS1), was first approved in 2011 by the United States (US) Food and Drug Administration (FDA) for treatment of patients with local advanced or metastatic ALK-positive NSCLC based on the results of early phase clinical trials [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.